WEKO3
アイテム
Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study
https://repository.lib.tottori-u.ac.jp/records/4652
https://repository.lib.tottori-u.ac.jp/records/465260c930dc-4ef4-45b5-b211-099d503bee39
| 名前 / ファイル | ライセンス | アクション |
|---|---|---|
yam65(3)_231.pdf (2.7 MB)
|
|
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2022-09-07 | |||||
| タイトル | ||||||
| タイトル | Efficacy of Combination Treatment with Tadalafil and Mirabegron in Patients with Benign Prostatic Hyperplasia Who Presented with Persistent Storage Symptoms After Tadalafil Monotreatment: A Prospective, Multicenter, Open-Labeled Study | |||||
| 言語 | en | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 主題 | benign prostatic hyperplasia | |||||
| キーワード | ||||||
| 主題 | combination treatment | |||||
| キーワード | ||||||
| 主題 | phosphodiesterase type 5 inhibitor | |||||
| キーワード | ||||||
| 主題 | storage symptoms | |||||
| キーワード | ||||||
| 主題 | β3-adrenoreceptor agonist | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | benign prostatic hyperplasia | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | combination treatment | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | phosphodiesterase type 5 inhibitor | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | storage symptoms | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題 | β3-adrenoreceptor agonist | |||||
| 資源タイプ | ||||||
| 資源タイプ | journal article | |||||
| 著者 |
本田, 正史
× 本田, 正史× 木村, 有佑× 川本, 文弥× 森實, 修一× 引田, 克弥× 武中, 篤× Teraoka, Shogo |
|||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 著者所属（英） | ||||||
| 言語 | en | |||||
| 値 | Division of Urology, Department of Surgery, School of Medicine, Faculty of Medicine, Tottori University | |||||
| 抄録 | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Background: The aim of this study is to evaluate the efficacy and safety of tadalafil, a phosphodiesterase type 5 inhibitor, plus mirabegron, a β3-adrenoreceptor agonist, in patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Methods: The registration of this study started in August 2016 and ended in July 2019. The inclusion criteria included patients aged ? 50 years who were diagnosed with benign prostatic hyperplasia and who presented with overactive bladder symptoms. Patients were treated with oral tadalafil 5 mg once daily for 4 weeks. Then, its efficacy was evaluated. Patients who responded to the treatment received oral tadalafil 5 mg once daily for 4 more weeks (monotreatment group). Meanwhile, those who did not respond received oral tadalafil 5 mg and mirabegron 50 mg, which is an add-on treatment, once daily for 4 more weeks (combination therapy group). Results: After 8 weeks, the monotreatment group (n = 19) and the combination group (n = 56) had significantly better total Overactive Bladder Symptom Score and International Prostate Symptom Score and International Prostate Symptom Score voiding and storage subscale scores. Moreover, the two groups experienced significant improvements in the total Overactive Bladder Questionnaire and Nocturia Quality of Life Questionnaire scores, and Nocturia Quality of Life Questionnaire Bother/Concern subscale score after 8 weeks. However, there were no cases of urinary retention or serious adverse events. Conclusion: Combination treatment with tadalafil and mirabegron is effective and safe for patients with benign prostatic hyperplasia who presented with persistent storage symptoms after tadalafil monotreatment. Hence, tadalafil plus mirabegron is a promising therapeutic option, and it can improve overactive bladder related-quality of life. | |||||
| 書誌情報 |
Yonago Acta Medica en : Yonago Acta Medica 巻 65, 号 3, p. 231-237, 発行日 2022-08-29 |
|||||
| 出版者 | ||||||
| 出版者 | Tottori University Medical Press | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 05135710 | |||||
| 書誌レコードID | ||||||
| 収録物識別子タイプ | NCID | |||||
| 収録物識別子 | AA00892882 | |||||
| DOI | ||||||
| 関連タイプ | isIdenticalTo | |||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | 10.33160/yam.2022.08.009 | |||||
| 権利 | ||||||
| 権利情報 | (C) 2022 Tottori University Medical Press. | |||||
| 情報源 | ||||||
| 関連名称 | Yonago Acta Medica. 2022, 65(3), 231-237. doi:10.33160/yam.2022.08.009 | |||||
| 関連サイト | ||||||
| 識別子タイプ | URI | |||||
| 関連識別子 | https://www.lib.tottori-u.ac.jp/yam/yam/yam65-3/65-3contents.html | |||||
| 関連名称 | https://www.lib.tottori-u.ac.jp/yam/yam/yam65-3/65-3contents.html | |||||
| 関連サイト | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.33160/yam.2022.08.009 | |||||
| 関連名称 | https://doi.org/10.33160/yam.2022.08.009 | |||||
| 著者版フラグ | ||||||
| 出版タイプ | VoR | |||||
| 出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
| EISSN | ||||||
| 値 | 13468049 | |||||
